At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,271 enrolled
Drug / intervention
Testosterone Transdermal System +1 moredrug
Likely dose
Testosterone Transdermal System 300 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.
In Brief
A Phase 3 clinical trial evaluating Testosterone Transdermal System and Placebo patch for Hypoactive Sexual Desire Disorder. Completed, enrolled 1,271 participants across 115 sites.
Detailed Summary
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoactive Sexual Desire Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedApr 2007
Primary CompletionJan 2009
TodayJul 2026
First PostedApr 30, 2007
Enrollment StartApr 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.2 years ago
Interventions
Testosterone Transdermal Systemdrug
Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Placebo patchdrug
placebo patch, changed twice a week for 52 weeks